Search

Your search keyword '"Orsini, I"' showing total 10 results
Start Over Author "Orsini, I"
10 results on '"Orsini, I"'

7. PCN208 COST-EFFECTIVENESS OF NIVOLUMAB FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH INVOLVEMENT OF LYMPH NODES OR METASTATIC DISEASE WHO HAVE UNDERGONE COMPLETE RESECTION: AN ANALYSIS FROM A SWISS HEALTHCARE SYSTEM PERSPECTIVE.

Author

Oniangue-Ndza, C., Strittmatter, G., Orsini, I., Teitsson, S., Augusto, M., and Amadi, A.

Subjects
*IPILIMUMAB, *LYMPH nodes, *COST effectiveness, *MELANOMA, *MEDICAL care, *SWISS franc
Abstract

The aim of this analysis was to assess the cost-effectiveness of nivolumab as an adjuvant treatment for adult patients with melanoma with involvement of lymph nodes or metastatic disease, from a healthcare system perspective in Switzerland. Recurrence-free survival (RFS) for nivolumab and observation was estimated through an indirect treatment comparison based on patient-level data from CheckMate 238 and CA184-029 trials, since both include ipilimumab as comparator. [Extracted from the article]

Published
2019
Full Text
View/download PDF

8. PCN192 COST-EFFECTIVENESS OF NIVOLUMAB FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH INVOLVEMENT OF LYMPH NODES OR METASTATIC DISEASE WHO HAVE UNDERGONE COMPLETE RESECTION IN GREECE.

Author

Augusto, M., Teitsson, S., Orsini, I., Diamantogiannis, F., Kouloumenta, A., and Amadi, A.

Subjects
*IPILIMUMAB, *LYMPH nodes, *COST effectiveness, *MELANOMA, *DISEASES, *THERAPEUTICS
Abstract

The objective of this study was to assess the cost-effectiveness of nivolumab as an adjuvant treatment of adult patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection, in Greece. Nivolumab presents an incremental cost-utility ratio of €8,611, €4,405 and €521 per QALY gained when compared to observation, high-dose interferon and low-dose interferon, respectively. [Extracted from the article]

Published
2019
Full Text
View/download PDF

9. PCN89 COST-EFFECTIVENESS OF NIVOLUMAB AS ADJUVANT TREATMENT OF MELANOMA IN ADULTS WITH INVOLVEMENT OF LYMPH NODES OR METASTATIC DISEASE WHO HAVE UNDERGONE COMPLETE RESECTION IN BELGIUM.

Author

Van Campenhout, H., Teitsson, S., Orsini, I., Augusto, M., and Amadi, A.

Subjects
*IPILIMUMAB, *LYMPH nodes, *COST effectiveness, *MELANOMA, *ADULTS, *DISCOUNT prices
Abstract

The aim of this study was to assess the cost-effectiveness of nivolumab versus "watch and wait" as an adjuvant treatment for melanoma in adults with involvement of lymph nodes or metastatic disease, after having undergone complete resection in Belgium. The efficacy of nivolumab and observation on recurrence free survival (RFS) was informed by an indirect treatment comparison based on patient-level data from CheckMate 238 (24-month cut-off data) and CA184-029 trials, as both include ipilimumab as comparator. [Extracted from the article]

Published
2019
Full Text
View/download PDF

10. PCN82 COST-EFFECTIVENESS OF NIVOLUMAB AS ADJUVANT TREATMENT OF MELANOMA IN ADULTS WITH INVOLVEMENT OF LYMPH NODES OR METASTATIC DISEASE WHO HAVE UNDERGONE COMPLETE RESECTION IN THE ITALIAN SETTING.

Author

Di Rienzo, P., Mennini, F.S., Marcellusi, A., Bini, C., Augusto, M., Orsini, I., Teitsson, S., and Amadi, A.

Subjects
*LYMPH nodes, *COST effectiveness, *MELANOMA, *ADULTS, *DISEASES
Abstract

The purpose of this analysis was to evaluate the cost-effectiveness of nivolumab as an adjuvant treatment for adults suffering from melanoma with involvement of lymph nodes or metastatic disease, after having undergone complete resection from the Italian healthcare system. Overall survival (OS) was modelled using an RFS/ OS correlation equation supported by published literature. [Extracted from the article]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results